ASYS AMTECH SYSTEMS INC Insider Trading

Director Averick Robert M bought 67,649 shares for $235,775.70 at blended $3.49 amid -39.7% 90-day decline.

Averick Robert M made 2 separate purchases totaling 67,649 shares for $235,775.70 at an average price of $3.49, increasing his holdings by 11.1% from 607,611 to 675,260 shares. The stock currently trades at $3.52, down -39.7% over the past 90 days from a 52-week high of $6.76. At the same ticker, his prior 5 buys have delivered mixed results: 3 recent March purchases remain unmeasurable at the 90-day horizon, while his February 2025 buys posted 90-day returns of -28.2% and -30.5%, with a 0% well-timed rate on measurable ASYS outcomes. The company is unprofitable with net income of $-31,812,000.00 and declining revenues (down 10.7% year-over-year), which provides fundamental context for the stock's extended downtrend and raises questions about the timing and conviction behind this director-level accumulation during sustained weakness.

ASYS Chair/CEO buys 7,853 shares ($27.4K) across 3 days; stock down -47.9% from 52-week high, company unprofitable

Robert C. Daigle, Chairman & CEO, executed 3 separate purchases totaling 7,853 shares (7.9K shares) for $27,353.42 ($27.4K) between May 14–16, 2025, at a blended average price of $3.48, increasing his holdings by 5.3% to 156,890 shares. The purchases occur in a challenging context: ASYS stock is currently down -47.9% from its 52-week high of $6.76, the company reported a negative net income of $-31,812,000.00 ($-31.8M) over its most recent full fiscal year, and annual revenue declined -10.7% year-over-year. Daigle's prior buy activity at this ticker shows mixed timing: 3 of 5 prior trades captured gains (90d returns of +12.4%, +8.5%, and +3.8%), while 2 prior buys in August 2023 were followed by declines. His cross-ticker track record across 13 prior buys averaged a -5.1% 90-day return with a 23.08% win rate, suggesting a history of entering positions before further declines. The current purchase at a significantly depressed price point, combined with the company's unprofitable status and negative revenue growth trajectory, presents a transaction that warrants monitoring of near-term stock performance to assess whether this represents a contrarian entry or continued deterioration.

ASYS Director Averick purchases 10,000 shares at $4.86 amid 4th buy in 8 days; stock down 11.6% in 90 days, company unprofitable.

Robert M Averick has completed 4 purchases of ASYS within the past 8 days—on 2024-12-13, 2025-02-07, 2025-02-13, 2025-03-03, and now 2025-03-10—accumulating shares during a period of declining stock price. The stock has fallen 11.6% over the past 90 days and trades at $4.97, down 26.5% from its 52-week high of $6.76. This rapid accumulation pattern is noteworthy given the company's fundamental weakness: it reported negative full-year net income, recent quarterly net income of only $312,000 on $24.4M revenue (1.3% margin), and faces declining revenue trends at -10.7% year-over-year growth. Averick's cross-ticker trading record shows a 46.67% 90-day win rate with modest average returns, but none of his 5 prior ASYS trades have yet produced positive 90-day returns, and his most recent prior trade (2024-12-13) was followed by a -4.6% 30-day decline. The sustained buying despite price deterioration and weak fundamentals stands out as the primary signal for investor attention.

Director Averick Robert M bought 6,523 shares across 2 purchases (blended avg $4.88) amid -26.8% drawdown from 52-week high.

Averick Robert M, a Director, made 2 separate open-market purchases totaling 6,523 shares for $31,836.55, raising his holdings from 582,789 to 589,312 shares. The purchases occurred at $4.89 (5,000 shares on 2025-03-03) and $4.85 (1,523 shares on 2025-03-05), representing a blended average price of $4.88, versus the current price of $4.95. The stock is trading -26.8% from its 52-week high of $6.76, and the company faces material headwinds: it reported negative full-year net income, annual revenue contracted -10.7%, and trades at a P/E of 61.88 despite posting only $312,000 in latest-quarter net income on $24,385,000 in revenue. Averick's cross-ticker track record shows a 60.00% 90-day win rate with an average 90-day return of +2.2%, but his prior 5 trades at ASYS have all been unprofitable at the 30-day mark (ranging from -4.6% to -5.8%), with measurable 90-day outcomes not yet available on any of those positions.

Director Averick Robert M bought 22,000 ASYS shares at $4.85 on 2025-02-13, now worth $5.62; stock -10.7% revenue growth, full-year net loss.

Director Averick Robert M purchased 22,000 shares of AMTECH SYSTEMS INC at $4.85, adding to a sequence of four prior ASYS buys within six weeks (2024-12-11 through 2025-02-13). His same-ticker history shows mixed near-term results: the August 2024 buy yielded a 90-day return of +4.0%, but the December buys generated 30-day losses of -5.0% to -5.8%. The stock has risen 7.0% over 30 days since this transaction, but fundamental conditions remain challenged—annual revenue declined 10.7%, the company posted a full-year net loss, and the P/E ratio stands at 70.25 despite a net income of $312,000 on quarterly revenue of $24.4M. The repeated accumulation pattern at declining valuations may reflect conviction, but the deteriorating fiscal trajectory and elevated valuation multiple warrant attention to whether sustained weakness could pressure the stock further.

Director Averick purchases 54.8K ASYS shares at $5.02; stock down 25.4% from 52-week high amid negative net income.

Director Robert M Averick purchased 54,789 shares of Amtech Systems at $5.02 on 2025-02-07, expanding his holdings by 10.8% to 560,789 shares. This represents a director's purchase of approximately $275.0K in a company trading at $5.04, down 25.4% from its 52-week high of $6.76 and down 6.2% over the last 30 days. At the same ticker, Averick has made 5 prior purchases, most recently on 2024-12-13, 2024-12-12, and 2024-12-11 (all declining 4–6% within 30 days); only 1 of his prior 5 ASYS trades showed a positive 90-day return. Fundamentally, Amtech reported quarterly revenue of $24.4M with net income of only $312.0K, negative annual growth of 10.7%, and a full-year loss, with a P/E of 63.00 reflecting significant valuation stress. Averick's cross-ticker record shows average 90-day returns of +1.9%, but his same-ticker pattern at ASYS shows a 20% 90-day win rate (1 of 5), suggesting prior purchases here have generally not recovered within 90 days.

Director Averick buys 32,000 shares (6.8% increase) for $181,625.00 at $5.68 avg across 3 days; stock -10.7% YoY revenue, unprofitable.

Director Robert M Averick purchased 32,000 shares across 3 consecutive trading days (Dec 11–13, 2024) at prices between $5.63 and $5.70, with a blended average of $5.68, increasing his holdings from 474,000 to 506,000 shares. The purchase occurred when the stock traded near its 52-week midpoint ($5.66 current vs $3.44–$6.76 range), down 16.3% from the 52-week high. At the same ticker, 3 of his 5 prior buys exhibited positive 90-day returns, including purchases made in August 2024 that showed 90-day gains of +11.2%, +4.0%, and -0.9%. However, the company's fundamentals are concerning: it reported -10.7% annual revenue growth and was unprofitable over its most recent full fiscal year despite $26.7M in latest-quarter revenue and $438.0K net income. The multi-day purchase pattern and sustained accumulation suggest deliberate positioning, though near-term headwinds (negative 90-day price trend of -6.3%) and negative earnings trajectory merit monitoring.

Director Averick Robert M purchased 40,000 shares of ASYS for $221,050.00 across 3 transactions (Aug 9–13, 2024) at blended avg $5.53

Averick Robert M (Director) executed 3 separate purchases totaling 40,000 shares for $221,050.00 during August 2024, raising his holdings by 9.2% to 474,000 shares. His prior 5 purchases at ASYS all achieved positive 90-day returns, with a timing pattern of 5 of 5 well-timed buys at the 90-day mark, indicating consistent buy discipline at this ticker. The August purchases were executed at $5.53 blended average against a current price of $5.48 (within the 52-week range of $3.44–$10.70), occurring during a -18.7% 30-day decline. The company remains unprofitable on a full-year basis despite $26.7M quarterly revenue and +6.6% annual revenue growth, providing limited fundamental support for the accumulation timing.